COMPANY PROFILE // THE 014 REPORT
Definium Therapeutics, Inc.
DFTX (Nasdaq) · Formerly: Mind Medicine (MindMed) Inc.
Assembled from 2 government sources in 2.0 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
No flag from the records checked. 26 of 26 lists and sources checked came back clear (panel below).
✓ SEC filings✓ Lobbying registrationpossible match✗ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website
No LEI, no SAM registration, no IRS return, no state registration, no website on record.
Definium Therapeutics, Inc. is an SEC-registered operating company in medicinal chemicals & botanical products, incorporated in British Columbia, Canada, based in New York, NY; listed as DFTX (Nasdaq).[source] It has filed 98 documents with the SEC in the last 12 months; the latest is a SCHEDULE 13G, filed 2026-11-16.[source] 2 lobbying disclosure filings name a client with this company's exact name (possible match).[source] Its largest institutional holders on 13F filings are BlackRock, Inc., Avoro Capital Advisors LLC, Driehaus Capital Management LLC (as of 2026-06-30).[source] Every list and source checked for this page came back clear (26 of 26), dated in the checks panel.[source]
- red0
- amber0
- info0
- BlackRock, Inc.$528.4M
- Avoro Capital Advisors LLC$338.2M
- Driehaus Capital Management LLC$322.0M
- Jupiter Topco LLC$264.0M
- Capital World Investors$252.5M
- FMR LLC$223.6M
- GEODE CAPITAL MANAGEMENT, LLC$171.5M
- STATE STREET CORP$144.2M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs. (Wikipedia, CC BY-SA 4.0)
Officers and directors (Forms 3, 4, 5)
- Barrow Robert · Chief Executive Officer (Director,Officer) · latest Form 4 2026-03-26 · filing · LinkedIn search
- Karlin Daniel · Chief Medical Officer (Officer) · latest Form 4 2026-03-26 · filing · LinkedIn search
- Roberts Brandi · Chief Financial Officer (Officer) · latest Form 4 2026-02-05 · filing · LinkedIn search
- Sullivan Mark · Chief Legal Officer (Officer) · latest Form 4 2026-03-26 · filing · LinkedIn search
- Wiley Matthew T. · Chief Commercial Officer (Officer) · latest Form 4 2026-02-05 · filing · LinkedIn search
- Adsett Roger · Director · latest Form 4 2026-01-29 · filing · LinkedIn search
- Bruhn Suzanne Louise · Director · latest Form 4 2025-06-16 · filing · LinkedIn search
- CRYSTAL ROGER · Director · latest Form 4 2025-06-16 · filing · LinkedIn search
- GRYSKA DAVID W · Director · latest Form 4 2025-06-16 · filing · LinkedIn search
- Krebs Andreas · Director · latest Form 4 2025-06-16 · filing · LinkedIn search
- Vallone Carol A · Director · latest Form 4 2025-06-16 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Links
- Official website (Wikidata or the SEC record)
- Wikipedia
- Wikidata
- LinkedIn company page (link only)
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001813814 | source |
| EIN | 00-0000000 | source |
| LDA clientpossible match | 65866 | record |
| LDA clientpossible match | 61913 | record |
| Business address (SEC) | ONE WORLD TRADE CENTER, NEW YORK, NY, 10007 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2833 (medicinal chemicals & botanical products): 43 companies in our records share this code.
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- USANA HEALTH SCIENCES INC · 103 SEC filings in 12 months
- Definium Therapeutics, Inc. · 98 SEC filings in 12 months
- Curaleaf Holdings, Inc. · 75 SEC filings in 12 months
- MARIMED INC. · 73 SEC filings in 12 months
- AURORA CANNABIS INC · 63 SEC filings in 12 months
- Canopy Growth Corp · 63 SEC filings in 12 months · 3 flags
- Trulieve Cannabis Corp. · 63 SEC filings in 12 months · 1 flag
- Cronos Group Inc. · 54 SEC filings in 12 months
- Tilray Brands, Inc. · 51 SEC filings in 12 months · 1 flag
- IM Cannabis Corp. · 51 SEC filings in 12 months
- Jushi Holdings Inc. · 47 SEC filings in 12 months
- MediWound Ltd. · 46 SEC filings in 12 months
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- INSMED Inc · Adsett Roger
- Travere Therapeutics, Inc. · Bruhn Suzanne Louise
- PLIANT THERAPEUTICS, INC. · Bruhn Suzanne Louise
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-09 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-09 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-09-25 filing 144 · SEC EDGAR
- 2026-09-25 filing 144 · SEC EDGAR
- 2026-09-25 filing 144 · SEC EDGAR
- 2026-09-25 filing 144 · SEC EDGAR
- 2026-09-25 filing 144 · SEC EDGAR
- 2026-09-14 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-09-08 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-09-03 filing 144 · SEC EDGAR
- 2026-08-12 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-08-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-06 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-06-25 filing 144 · SEC EDGAR
- 2026-06-25 filing 144 · SEC EDGAR
- 2026-06-25 filing 144 · SEC EDGAR
- 2026-06-25 filing 144 · SEC EDGAR
- 2026-06-25 filing 144 · SEC EDGAR
- 2026-06-24 filing 8-K items 1.01,8.01,9.01 · SEC EDGAR
- 2026-06-24 filing 424B5 · SEC EDGAR
- 2026-06-22 filing 424B5 · SEC EDGAR
- 2026-06-22 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-06-16 filing S-8 · SEC EDGAR
- 2026-06-12 officer change 8-K items 5.02,5.07,9.01 · SEC EDGAR
- 2026-05-19 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-05-12 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-05-07 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-07 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-27 filing DEFA14A · SEC EDGAR
- 2026-04-27 filing Proxy statement · SEC EDGAR
170 earlier entries
- 2026-04-22 filing 8-K items 8.01,9.01
- 2026-03-25 filing 144
- 2026-03-25 filing 144
- 2026-03-25 filing 144
- 2026-02-26 filing Annual report (10-K)
- 2026-02-26 filing 8-K items 2.02,9.01
- 2026-02-05 insider First Form 3/4/5 on record for Wiley Matthew T. (Chief Commercial Officer)
- 2026-01-29 officer change 8-K items 5.02
- 2026-01-29 insider First Form 3/4/5 on record for Adsett Roger (Director)
- 2026-01-12 filing 8-K items 2.02,5.03,8.01,9.01
- 2026-01-12 name change Name changed from Mind Medicine (MindMed) Inc.
- 2025-12-29 filing 144
- 2025-12-29 filing 144
- 2025-12-29 filing 144
- 2025-11-06 filing Quarterly report (10-Q)
- 2025-11-06 filing 8-K items 2.02,8.01,9.01
- 2025-10-31 filing 8-K items 1.01,8.01,9.01
- 2025-10-31 filing 424B5
- 2025-10-29 filing 8-K items 2.02,8.01,9.01
- 2025-10-29 filing 424B5
- 2025-09-25 filing 144
- 2025-09-25 filing 144
- 2025-09-25 filing 144
- 2025-09-04 filing 8-K items 8.01,9.01
- 2025-07-31 filing Quarterly report (10-Q)
- 2025-07-31 filing 8-K items 2.02,8.01,9.01
- 2025-06-26 insider First Form 3/4/5 on record for Barrow Robert (Chief Executive Officer)
- 2025-06-26 insider First Form 3/4/5 on record for Karlin Daniel (Chief Medical Officer)
- 2025-06-26 insider First Form 3/4/5 on record for Sullivan Mark (Chief Legal Officer)
- 2025-06-25 filing 144
- 2025-06-25 filing 144
- 2025-06-25 filing 144
- 2025-06-20 filing S-8
- 2025-06-16 officer change 8-K items 5.02,5.07,9.01
- 2025-06-16 insider First Form 3/4/5 on record for Bruhn Suzanne Louise (Director)
- 2025-06-16 insider First Form 3/4/5 on record for CRYSTAL ROGER (Director)
- 2025-06-16 insider First Form 3/4/5 on record for GRYSKA DAVID W (Director)
- 2025-06-16 insider First Form 3/4/5 on record for Krebs Andreas (Director)
- 2025-06-16 insider First Form 3/4/5 on record for Vallone Carol A (Director)
- 2025-06-02 insider First Form 3/4/5 on record for Roberts Brandi (Chief Financial Officer)
- 2025-05-27 officer change 8-K items 5.02,7.01,9.01
- 2025-05-08 filing Quarterly report (10-Q)
- 2025-05-08 filing 8-K items 2.02,9.01
- 2025-05-05 filing D
- 2025-04-23 filing ARS
- 2025-04-23 filing DEFA14A
- 2025-04-23 filing Proxy statement
- 2025-04-21 filing 8-K items 1.01,2.03,3.02,9.01
- 2025-04-15 filing 8-K items 8.01,9.01
- 2025-03-25 filing 144
- 2025-03-25 filing 144
- 2025-03-25 filing 144
- 2025-03-25 filing 144
- 2025-03-06 filing Annual report (10-K)
- 2025-03-06 filing 8-K items 2.02,9.01
- 2025-01-30 filing 8-K items 8.01,9.01
- 2025-01-13 officer change 8-K items 5.02,8.01,9.01
- 2024-12-26 filing 144
- 2024-12-26 filing 144
- 2024-12-26 filing 144
- 2024-12-26 filing 144
- 2024-12-16 filing 8-K items 8.01,9.01
- 2024-11-07 filing Quarterly report (10-Q)
- 2024-11-07 filing 8-K items 2.02,9.01
- 2024-10-22 filing 424B3
- 2024-10-17 filing 8-K items 1.01,3.02,8.01,9.01
- 2024-10-17 filing 424B7
- 2024-09-25 filing 144
- 2024-09-25 filing 144
- 2024-09-25 filing 144
- 2024-08-13 filing Quarterly report (10-Q)
- 2024-08-13 filing 8-K items 2.02,9.01
- 2024-08-12 filing 8-K items 1.01,2.02,8.01,9.01
- 2024-08-12 filing 424B5
- 2024-08-09 filing 424B5
- 2024-06-28 filing 8-K items 1.01,8.01,9.01
- 2024-06-28 filing S-3ASR
- 2024-06-28 filing S-8
- 2024-06-25 filing 144
- 2024-06-25 filing 144
- 2024-06-25 filing 144
- 2024-06-20 filing 8-K items 8.01,9.01
- 2024-06-11 filing 8-K items 5.07
- 2024-05-08 filing Quarterly report (10-Q)
- 2024-05-08 filing 8-K items 2.02,9.01
- 2024-04-30 filing 424B3
- 2024-04-30 filing 424B3
- 2024-04-29 filing EFFECT
- 2024-04-26 filing CORRESP
- 2024-04-26 filing ARS
- 2024-04-26 filing DEFA14A
- 2024-04-26 filing Proxy statement
- 2024-04-09 filing UPLOAD
- 2024-04-02 filing S-3
- 2024-04-01 filing 8-K items 8.01,9.01
- 2024-03-25 filing 144
- 2024-03-25 filing 144
- 2024-03-18 filing D
- 2024-03-11 filing 8-K items 1.01,3.02,8.01,9.01
- 2024-03-08 filing 424B5
- 2024-03-07 filing 8-K items 7.01,9.01
- 2024-03-07 filing S-3MEF
- 2024-03-07 filing 8-K items 7.01,8.01,9.01
- 2024-03-01 filing 144
- 2024-02-28 filing Annual report (10-K)
- 2024-02-28 filing 8-K items 2.02,9.01
- 2024-01-08 filing 8-K items 7.01,9.01
- 2023-12-26 filing 144
- 2023-12-26 filing 144
- 2023-12-26 filing 144
- 2023-12-14 filing 8-K items 7.01,8.01,9.01
- 2023-11-02 filing Quarterly report (10-Q)
- 2023-11-02 filing 8-K items 2.02,7.01,9.01
- 2023-09-25 filing 144
- 2023-09-25 filing 144
- 2023-09-25 filing 144
- 2023-09-15 filing 8-K/A items 8.01
- 2023-09-15 filing 8-K/A items 8.01
- 2023-08-28 filing 144
- 2023-08-28 filing 144
- 2023-08-14 filing 8-K items 7.01,8.01,9.01
- 2023-08-14 filing 8-K items 1.01,2.03,3.02,9.01
- 2023-08-03 filing Quarterly report (10-Q)
- 2023-08-03 filing 8-K items 2.02,9.01
- 2023-07-25 filing 8-K/A items 5.07
- 2023-06-27 filing 8-K items 5.07
- 2023-06-20 filing 8-K items 7.01,9.01
- 2023-06-16 filing DEFA14A
- 2023-06-16 filing 8-K items 8.01
- 2023-06-16 filing DFAN14A
- 2023-06-15 filing DFAN14A
- 2023-06-15 filing 8-K items 8.01,9.01
- 2023-06-15 filing DEFA14A
- 2023-06-12 filing DFAN14A
- 2023-06-12 filing DEFA14A
- 2023-06-09 filing DFAN14A
- 2023-06-09 filing DEFA14A
- 2023-06-08 filing DFAN14A
- 2023-06-08 filing DEFA14A
- 2023-06-08 filing DEFA14A
- 2023-06-07 filing DFAN14A
- 2023-06-06 filing DFAN14A
- 2023-06-05 filing DFAN14A
- 2023-06-05 filing DEFA14A
- 2023-06-05 filing DEFA14A
- 2023-06-02 filing DFAN14A
- 2023-06-01 filing DFAN14A
- 2023-05-31 filing DEFA14A
- 2023-05-31 filing DFAN14A
- 2023-05-31 filing DEFA14A
- 2023-05-30 filing DFAN14A
- 2023-05-25 filing DFAN14A
- 2023-05-25 filing DEFA14A
- 2023-05-25 filing DEFA14A
- 2023-05-25 filing DEFA14A
- 2023-05-24 filing DFAN14A
- 2023-05-24 filing 8-K items 7.01,8.01,9.01
- 2023-05-24 filing DEFA14A
- 2023-05-22 filing DEFA14A
- 2023-05-18 filing DEFA14A
- 2023-05-17 filing 8-K items 2.02,8.01,9.01
- 2023-05-15 filing DFAN14A
- 2023-05-12 filing DEFA14A
- 2023-05-12 filing DEFA14A
- 2023-05-12 filing DEFA14A
- 2023-05-09 filing DEFA14A
- 2023-05-05 filing DFAN14A
- 2023-05-04 filing DEFA14A
- 2023-05-04 filing Quarterly report (10-Q)
- 2023-05-04 filing 8-K items 2.02,9.01
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-09 (within 30 days) 10-Q filed
- 2026-11-09 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-09-14 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-09-08 (older) 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-08-12 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-08-06 (older) 10-Q filed
- 2026-08-06 (older) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-06-24 (older) 8-K filed: Item 1.01 material agreement; Item 8.01 other event; Item 9.01 exhibits
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-21; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:DFTX The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
3 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1813814 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | DFTX / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| CUSIP | 24477V105 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001813814 | SEC EDGAR |
possible match: matched by name only, not merged (2)
Identifiers carried by records that share the company's exact name. Not merged into the identity above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| LDA client id | 65866 (DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) (lobbying via DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.))) | name-exact: exact name match to 'Definium Therapeutics, Inc.' (no other entity shares the name) | Lobbying Disclosure Act (LDA) |
| LDA client id | 61913 (DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) (lobbying via THE CONAFAY GROUP, LLC)) | name-exact: exact name match to 'Definium Therapeutics, Inc.' (no other entity shares the name) | Lobbying Disclosure Act (LDA) |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Net income (loss) (fiscal year ended 2025-12-31) | -$183,793,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-21 00:25 UTC | Report an error |
| Total assets (at 2025-12-31) | $440,100,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-21 00:25 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $332,327,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-21 00:25 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $257,837,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-21 00:25 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 00:25 UTC | Report an error |
| SIC industry | 2833 Medicinal Chemicals & Botanical Products | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 00:25 UTC | Report an error |
| State of incorporation | A1 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 00:25 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 00:25 UTC | Report an error |
| Business address | ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK, NY, 10007 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 00:25 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 00:25 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$131,560,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-21 00:25 UTC | Report an error |
| Long-term debt (at 2025-12-31) | $40,579,000 | 2025-12-31 | 10-K, XBRL LongTermDebtNoncurrent | as filed | 2026-11-21 00:25 UTC | Report an error |
| Form D total offering amount (D filed 2025-05-05) | $7,000,000 | 2025-05-05 | D | as filed | 2026-11-21 00:25 UTC | Report an error |
| Form D total amount sold (D filed 2025-05-05) | $7,000,000 | 2025-05-05 | D | as filed | 2026-11-21 00:25 UTC | Report an error |
| Form D industry group | Pharmaceuticals | 2025-05-05 | D | as filed | 2026-11-21 00:25 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2025-05-05 | D | as filed | 2026-11-21 00:25 UTC | Report an error |
| Form D date of first sale | 2023-08-11 | 2025-05-05 | D | as filed | 2026-11-21 00:25 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-09 · accession 0001193125-26-453626
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$50,961,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-09 | 0001193125-26-453626 | 2026-11-21 00:25 UTC | Report an error |
| Interest expense | $1,150,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-09 | 0001193125-26-453626 | 2026-11-21 00:25 UTC | Report an error |
| Cash and cash equivalents | $241,150,000 | at 2026-09-30 | 10-Q | 2026-11-09 | 0001193125-26-453626 | 2026-11-21 00:25 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-09 Filing 10-Q filed
- 2026-11-09 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-09-14 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-09-08 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-08-12 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-08-06 Filing 10-Q filed
- 2026-08-06 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-06-24 Filing 8-K filed: Item 1.01 material agreement; Item 8.01 other event; Item 9.01 exhibits
- 2026-06-24 Filing 424B5 filed
- 2026-06-22 Filing 424B5 filed
- 2026-06-22 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-06-16 Filing S-8 filed (FORM S-8)
- 2026-06-12 Filing 8-K filed: Item 5.02 officer or director change; Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-05-19 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-05-12 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-05-07 Filing 10-Q filed
- 2026-05-07 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-27 Filing DEFA14A filed
- 2026-04-27 Filing DEF 14A filed
- 2026-04-22 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-02-26 Filing 10-K filed
- 2026-02-26 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-01-29 Filing 8-K filed: Item 5.02 officer or director change
- 2026-01-12 Filing 8-K filed: Item 2.02 results of operations; Item 5.03 charter or bylaw amendment; Item 8.01 other event; Item 9.01 exhibits
- 2025-11-06 Filing 10-Q filed
8-K item text, as filed (excerpts)
- 2026-11-09 8-K Item 2.02, Results of Operations and Financial Condition
On November 9, 2026, Definium Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter ended September 30, 2026, as well as information regarding a conference call to discuss these financial results and the Company’s recent corporate highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02. The information contained in this Item 2.02 of this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or… the 8-K · retrieved 2026-11-21 00:25 UTC - 2026-09-14 8-K Item 7.01, Regulation FD Disclosure
On September 14, 2026, Definium Therapeutics, Inc. (the “Company”) issued a press release (the “Press Release”) announcing positive topline data from the Company’s Phase 3 Panorama study of DT120 ODT for the treatment of generalized anxiety disorder. A copy of the Press Release is attached as Exhibit 99.1 hereto, and is incorporated by reference into this Item 7.01. The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into… the 8-K · retrieved 2026-11-21 00:25 UTC - 2026-09-14 8-K Item 8.01, Other Events
On September 14, 2026, the Company posted a presentation discussing the Panorama topline data (the “Presentation”) to its website. A copy of the Presentation is attached as Exhibit 99.2 hereto, and is incorporated by reference into this Item 8.01. the 8-K · retrieved 2026-11-21 00:25 UTC - 2026-09-08 8-K Item 8.01, Other Events
On September 8, 2026, Definium Therapeutics, Inc. (the “Company”) issued a press release (the “Press Release”) announcing that the U.S. Food and Drug Administration has granted breakthrough designation to the Company’s DT120 ODT program for the treatment of major depressive disorder. A copy of the Press Release is attached as Exhibit 99.1 hereto, and is incorporated by reference herein. the 8-K · retrieved 2026-11-21 00:25 UTC - 2026-08-12 8-K Item 7.01, Regulation FD Disclosure
On August 12, 2026, Definium Therapeutics, Inc. (the “Company”) issued a press release (the “Press Release”) announcing positive topline data from the Company’s Phase 3 Voyage study of DT120 ODT for the treatment of generalized anxiety disorder. A copy of the Press Release is attached as Exhibit 99.1 hereto, and is incorporated by reference into this Item 8.01. The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of… the 8-K · retrieved 2026-11-21 00:25 UTC - 2026-08-12 8-K Item 8.01, Other Events
On August 12, 2026, the Company posted a presentation discussing the Voyage topline data (the “Presentation”) to its website. A copy of the Presentation is attached as Exhibit 99.2 hereto, and is incorporated by reference into this Item 8.01. the 8-K · retrieved 2026-11-21 00:25 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · NAME ONLY6. Lobbying (LDA)
2 lobbying records carry this company's exact name, hiring 2 lobbying firms. These are possible matches until the accuracy score, so they are not counted in the headline.
possible match: matched by name only, not merged (2)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchDEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) (lobbying via DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.)) · exact name match to 'Definium Therapeutics, Inc.' (no other entity shares the name) · sx:lda:65866 Compare
- possible matchDEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) (lobbying via THE CONAFAY GROUP, LLC) · exact name match to 'Definium Therapeutics, Inc.' (no other entity shares the name) · sx:lda:61913 Compare
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | $528,392,511 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:25 UTC | Report an error |
| 2 | Avoro Capital Advisors LLC | $338,165,292 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:25 UTC | Report an error |
| 3 | Driehaus Capital Management LLC | $322,001,783 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:25 UTC | Report an error |
| 4 | Jupiter Topco LLC | $264,002,611 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:25 UTC | Report an error |
| 5 | Capital World Investors | $252,497,690 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:25 UTC | Report an error |
| 6 | FMR LLC | $223,577,402 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:25 UTC | Report an error |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | $171,482,802 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:25 UTC | Report an error |
| 8 | STATE STREET CORP | $144,195,946 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:25 UTC | Report an error |
| 9 | Capital International Investors | $139,398,806 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:25 UTC | Report an error |
| 10 | Octagon Capital Advisors LP | $138,768,000 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:25 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
1 state and city record carry this company's exact name, from 1 source. Possible matches only.
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchDefinium Therapeutics US, Inc. · exact name match to 'Definium Therapeutics, Inc.' (no other entity shares the name) · sx:ctgov:h7b89521bf2c15b6c Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1813814.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001813814. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.